Zn2SiO4Bioceramic Attenuates Cardiac Remodeling after Myocardial Infarction

In the pursuit of therapeutic strategies for myocardial infarction (MI), a pivotal objective lies in the concurrent restoration of blood perfusion and reduction of cardiomyocyte apoptosis. However, achieving these dual goals simultaneously presents a considerable challenge. In this study, a Zn2SiO4bioceramic capable of concurrently sustaining the release of bioactive SiO32−and Zn2+ions, which exhibit a synergistic impact on endothelial cell angiogenesis promotion, cardiomyocyte apoptosis inhibition, and myocardial mitochondrial protection against oxygen‐free radical (reactive oxygen species) induced injury is developed. Furthermore, in vivo outcomes from a murine MI model demonstrate that either systemic administration via tail vein injection of Zn2SiO4extract or local application through intramyocardial injection of a Zn2SiO4composite hydrogel promotes cardiac function and reduces cardiac fibrosis, thus aiding myocardial repair. This research is the first to elucidate the advantageous effects of dual bioactive ions in myocardial protection and may offer a novel therapeutic avenue for ischemic heart disease based on meticulously engineered bioceramics. The bioactive Zn2+and SiO32−ions derived from Zn2SiO4bioceramic can inhibit pathological cardiac remodeling and promote myocardial repair in mice after myocardial infarction in different forms including ions extract for systemic therapy (tail intravenous injection) and composite hydrogel for local therapy (intramyocardial injection) by promotion of angiogenesis, protection of myocardial mitochondrial, and inhibition of cardiomyocyte apoptosis.